Journal of Medical Toxicology

, Volume 2, Issue 2, pp 51–54 | Cite as

Conflicts of interest: Bias or boon?

  • Christian Tomaszewski


conflicts of interest research funding research bias 


  1. 1.
    Mayor S. Surgery journal bans authors who hide conflicts of interest. BMJ2006; 332: 135.PubMedCrossRefGoogle Scholar
  2. 2.
    Armstrong D. Surgery journal threatens ban for authors’ hidden conflicts. Wall Street Journal 28 Dec2005; B1.Google Scholar
  3. 3.
    Study Finds That Medical Research is Often Wrong. Associated Press. 14 July2005. Available from: story/0, 2933, 162441, 00.htmlGoogle Scholar
  4. 4.
    Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA2005; 294(2): 218–228.PubMedCrossRefGoogle Scholar
  5. 5.
    FDA. New and generic drug approvals. Drugs@FDA Data Files. 22 Feb2006. Available from: drugsatfda/datafiles/default.htm.Google Scholar
  6. 6.
    DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Economics2003; 22: 151–185.CrossRefGoogle Scholar
  7. 7.
    PhRMA Annual Report 2005–2006. 1–32.2006. Available from: Scholar
  8. 8.
    Aoki N. Trials and errors. Boston Globe. 12 June2002.Google Scholar
  9. 9.
    Bekelman J, Li Y, Gross C. Scope and impact of financial conflicts of interest in biomedical research. JAMA2003; 289: 454–465.PubMedCrossRefGoogle Scholar
  10. 10.
    Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. American Journal of Psychiatry2005; 162: 1957–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Kjaergard LL, Als-Nielsen B. Association between competing interests and authors’ conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ2002; 325: 429.CrossRefGoogle Scholar
  12. 12.
    Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR et al. The uncertainty principle and industry-sponsored research. Lancet2000; 356: 635–638.PubMedCrossRefGoogle Scholar
  13. 13.
    Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA1999; 282: 1453–1457.PubMedCrossRefGoogle Scholar
  14. 14.
    Stelfox HT, Chua G, O’Rourke K, Detsky AS. Confict of interest in the debate over calcium-channel antagonists. N Engl J Med1998; 338: 101–106.PubMedCrossRefGoogle Scholar
  15. 15.
    Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.[see comment]. CMAJ Canadian Medical Association Journal2004; 170(4): 477–80.Google Scholar
  16. 16.
    Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: A reflection of treatment effect of adverse events? JAMA2003; 290: 921–928.PubMedCrossRefGoogle Scholar
  17. 17.
    Gottlieb S. Firm tried to block report on failure of AIDS vaccine. BMJ2000; 321: 1173.PubMedCrossRefGoogle Scholar
  18. 18.
    Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 Immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 106 /L CD4 cell counts: A randomized controlled trial. JAMA2000; 284: 2193–2202.PubMedCrossRefGoogle Scholar
  19. 19.
    Rennie D. Thyroid storm. JAMA1997; 277: 1238–1243.PubMedCrossRefGoogle Scholar
  20. 20.
    Dong B, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA1997; 277: 1205–1213.PubMedCrossRefGoogle Scholar
  21. 21.
    U.S.District Court. Synthroid Marketing Litigation. 97 C 6017. 2000. Northern District of Illinois, Eastern Division. 1 Nov1999. Scholar
  22. 22.
    Kowalczyk L. Use of drug soars despite controversy. Boston Globe 25 Nov2002; A1.Google Scholar
  23. 23.
    Kowalczyk L. Drug company push on doctors disclosed. Boston Globe 19 May2002; A1.Google Scholar
  24. 24.
    Harris G. Pfizer to pay $430 million over promoting drug to doctors. New York Times 14 May2004; C1.Google Scholar
  25. 25.
    Goozner M. Unrevealed: Non-disclosure of conflicts of interest in four leading medical and scientific journals. 1–16. 12 July2004. Washington, D.C., Center for Science in the Public Interest.Google Scholar
  26. 26.
    Tuech JJ, Moutel G, Pessaux P, Thoma V, Schraub S, Herve C. Disclosure of competing financial interests and role of sponsors in phase III cancer trials. European Journal of Cancer2005; 41: 2237–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Weiss R. Deception by scientists relatively rare. Washington Post 15 Jan2006; A19.Google Scholar
  28. 28.
    Musher DM, Stone PH. Undisclosed Conflicts of Interest. Annals of Internal Medicine2006; 144:225.PubMedGoogle Scholar
  29. 29.
    Bevan JC. Ethical behaviour of authors in biomedical journalism. Annals of the Royal College of Physicians and Surgeons of Canada2002; 35: 81–85.Google Scholar
  30. 30.
    Drazen JM, Curfman GD. Financial associations of authors. N Engl J Med2002; 346: 1901–1902.PubMedCrossRefGoogle Scholar
  31. 31.
    James A, Horton R, Collingridge D, McConnell J, Butcher J. The Lancet’s policy on conflicts of interest. Lancet2004; 363: 2–3.PubMedCrossRefGoogle Scholar
  32. 32.
    Publishing commentary by authors with potential conflicts of interest: when, why, and how.[comment]. Annals of Internal Medicine2004; 141: 73–4.Google Scholar
  33. 33.
    International Committee of Medical Journal Editors. Uniform requirements for mansucripts submitted to biomedical journals: Writing and editing for biomedical publication. 1–35.2006. Scholar

Copyright information

© American College of Medical Toxicology 2006

Authors and Affiliations

  1. 1.Dept of Emerg MedCarolinas Medical CenterCharlotte

Personalised recommendations